Trauma and Substance Use Disorders: Comorbidity and Treatment

Author: Angela Bogdanova · Published: October 19, 2026 · Editorial Policy

Research cluster: Substance Use Disorders and Addiction Recovery · Written by Artificial Sapiens

Understanding the Relationship Between Trauma and Substance Use Disorders

Trauma and substance use disorders frequently intersect in clinical practice. People exposed to violence, abuse, war, serious accidents, or other potentially traumatic events may use alcohol or drugs in an attempt to manage distress, insomnia, fear, pain, or intrusive memories. Some develop a substance use disorder (SUD), while others experience trauma-related symptoms without meeting criteria for posttraumatic stress disorder (PTSD). A person may also develop PTSD and an SUD independently through partly shared developmental, social, and biological vulnerabilities. Effective clinical care evaluates these possibilities rather than assuming that substance use always originates in trauma.

The central finding of contemporary treatment research is that people with co-occurring PTSD and SUD can receive evidence-based care for both conditions, including appropriately delivered trauma-focused psychotherapy alongside substance-specific addiction treatment. Co-occurring SUD is not, by itself, a reason to withhold effective PTSD treatment. This position is reflected in the 2023 VA/DoD PTSD clinical practice guideline, in the VA National Center for PTSD clinical synthesis, and in Project Harmony's comparative evidence. Care still begins with individual assessment of intoxication, withdrawal risk, suicidality, medical stability, consent, and the person's circumstances.

This article examines how trauma exposure and substance use disorders become associated, the difference between traumatic stress and a PTSD diagnosis, mechanisms that may sustain both problems, the evidence for concurrent and integrated treatment, clinical safety decisions, and the longer-term conditions that support recovery. General PTSD treatment, broad addiction diagnosis, and anxiety-related substance use retain distinct clinical questions; the focus here is their intersection.

Trauma Exposure, Traumatic Stress, PTSD, and Substance Use Disorder

What qualifies as trauma in clinical assessment?

In everyday speech, trauma may refer to many painful or destabilizing experiences. In DSM-5-TR PTSD assessment, the exposure criterion is narrower: exposure to actual or threatened death, serious injury, or sexual violence through specified direct, witnessed, learned-about, or occupationally repeated pathways. Clinicians also assess chronic adversity, discrimination, family violence, neglect, displacement, and cumulative stress because these can shape health and addiction vulnerability even when a particular experience does not satisfy the DSM PTSD exposure criterion. The distinction matters for diagnostic accuracy and does not diminish the importance of a person's suffering.

Trauma exposure is an event history; traumatic stress is a set of responses; PTSD is a specific diagnosis requiring qualifying exposure, characteristic symptom clusters, duration, impairment, and exclusion of substance-induced or other explanations. Many trauma-exposed people do not develop PTSD. Others experience clinically important depression, anxiety, dissociation, sleep problems, or interpersonal difficulties. The VA CAPS-5 assessment guidance describes the structured diagnostic evaluation of exposure, symptoms, timing, and functioning.

What makes substance use a disorder?

Substance use denotes consumption or exposure; risky use denotes patterns associated with increased harm; substance misuse is a variable everyday or clinical expression whose meaning depends on context. SUD refers to a diagnostically significant pattern involving such features as impaired control, sustained use despite harm, craving, hazardous use, role impairment, or related criteria. DSM-5-TR severity depends on the number of applicable criteria. A person can use a substance following trauma without developing an SUD, and an SUD can develop without identified trauma exposure.

Tolerance and physical dependence reflect physiological adaptation and can appear during appropriate prescribed treatment. Withdrawal is a substance-specific syndrome after reduction or cessation following adaptation. These features alone do not establish compulsive addiction. Conversely, compulsive use with serious impairment can meet SUD criteria without prominent physical withdrawal. Acute intoxication, overdose, and withdrawal require distinct assessment from the enduring disorder and from PTSD. The SAMHSA co-occurring disorders guidance emphasizes assessing both conditions in their own right.

What does comorbidity mean here?

Comorbidity means that two diagnosable conditions occur in the same person within the relevant period. PTSD with alcohol use disorder, PTSD with opioid use disorder, and PTSD with stimulant use disorder are clinically different combinations. Trauma exposure without diagnosable PTSD plus an SUD also deserves trauma-informed care, but should not be counted as PTSD-SUD comorbidity. Mental-health symptoms that arise mainly during intoxication or withdrawal may require reassessment after stabilization before assigning an independent trauma-related disorder.

How Common Is the Overlap?

Population surveys and treatment cohorts consistently report substantial associations between PTSD and substance use disorders, although prevalence changes with diagnostic definitions, substance class, sampling frame, sex, age, exposure history, and whether current or lifetime diagnoses are counted. A U.S. national epidemiologic analysis summarized by the VA National Center for PTSD reported that 44.6% of respondents with lifetime PTSD had also met lifetime criteria for an alcohol or other drug use disorder. That statistic is a lifetime co-occurrence finding from a particular survey, not the probability that any trauma-exposed person will develop addiction.

Clinical prevalence is often higher than community prevalence because treatment programs select for greater severity and help-seeking. Veteran studies contain distinctive exposure patterns and healthcare pathways; findings require caution before generalization to civilians, adolescents, or populations with different patterns of substance availability. Trauma is common among people entering SUD care, but trauma history alone does not identify which individuals have PTSD, how severe their addiction is, or which treatment they will prefer.

The consequences of co-occurrence can be cumulative: symptoms may interfere with sleep, concentration, appointments, social relationships, employment, physical safety, and engagement in treatment. Studies associate the combination with greater psychiatric complexity and functional burdens than either disorder alone. These are group-level associations. Individual prognosis depends on symptoms, available care, housing and social support, substance-specific risk, current safety, and response to treatment. The VA evidence summary describes this heterogeneity and the need for measurement-based, shared decisions.

Why Trauma and Substance Use Disorders Become Linked

Negative reinforcement and short-term relief

One influential mechanism is negative reinforcement. Alcohol, sedatives, opioids, or other substances may temporarily reduce distressing arousal, emotional pain, insomnia, or awareness of reminders. When discomfort decreases, the behavior becomes more likely to recur. The immediate relief can obscure accumulating harms: sleep disruption, withdrawal, impaired judgment, renewed anxiety, and reduced opportunity to learn durable coping strategies. This account explains an important pathway in some patients but does not establish that every instance of alcohol or drug use is an attempt at self-medication.

The emotional state before use, the effects during intoxication, the rebound after drug effects diminish, and the situations in which use is repeated all matter. For one person, trauma reminders dominate; for another, social pressure or pain may be more influential. Substance effects also vary: an activating stimulant can intensify hyperarousal and insomnia, while alcohol may produce short-term sedation followed by fragmented sleep and increased anxiety. Clinicians therefore investigate observable patterns rather than presuming a uniform psychological motive.

Stress systems, reward learning, and cue reactivity

Repeated severe stress can influence threat monitoring, autonomic arousal, memory, emotion regulation, and decision-making. Substance use and withdrawal also affect learning, stress responsiveness, motivation, and attention to drug cues. Trauma reminders may become paired with substance availability or craving; a context associated with an assault, an anniversary, an interpersonal conflict, or a state of hypervigilance may precede both PTSD symptoms and an urge to use. These processes can reinforce one another over time.

Human neurobiological findings are heterogeneous and are shaped by stress history, development, substance class, medication, and co-occurring illness. Neuroimaging and stress biomarkers describe potential mechanisms but cannot diagnose the cause of addiction in a particular patient. A convincing explanation joins biological findings to longitudinal behavior, environmental exposures, and clinical assessment. Reviews of PTSD-SUD treatment emphasize the importance of behavioral targets rather than translating a single neural correlate into an individual prediction; see Project Harmony.

Shared risk factors and developmental pathways

Adversity can co-occur with family substance use, genetic vulnerability, disrupted caregiving, chronic poverty, instability, or increased substance access. Some common factors precede both PTSD and SUD. Others develop after a trauma or after substance exposure. A trauma history can increase risk without being either necessary or sufficient for either diagnosis. Similarly, PTSD symptoms may precede escalating substance use in one person, while heavy use and associated exposure to violence may precede traumatic events in another. Bidirectional pathways are plausible and may coexist.

Longitudinal research is especially valuable because cross-sectional comorbidity cannot determine which condition caused the other. Retrospective memories of onset may be inaccurate; unmeasured confounding can shape observed associations. Effective treatment does not require proving a single causal sequence. It requires identifying the treatable processes that maintain impairment now and the supports that can alter their course.

Avoidance, shame, dissociation, and interpersonal safety

Avoidance is central to many PTSD presentations and can overlap with avoiding withdrawal discomfort, conflict, or reminders of substance-related harm. Shame and fear of judgment can delay disclosure of sexual violence, family abuse, or substance use. Dissociation may make it difficult to track time, communicate distress, or feel present in psychotherapy, yet dissociation is also reported in other mental disorders and during intoxication. Assessment must consider these alternatives rather than treating dissociation as definitive proof of trauma or PTSD.

A person experiencing ongoing violence, unsafe housing, coercion, or an unstable supply of medication may face continual threats that undermine therapy participation. Trauma-informed clinical procedures improve predictability, confidentiality, choice, and collaboration so that assessment itself does not unnecessarily reproduce loss of control. SAMHSA's trauma-informed approach describes safety, trustworthiness, peer support, shared decision-making, and empowerment as core organizational principles.

Clinical Presentation and the Differential Diagnosis

Recognizing overlapping symptoms

Sleep disturbance, irritability, heightened vigilance, panic-like symptoms, concentration problems, depressed mood, and social withdrawal may appear in PTSD, substance intoxication, substance withdrawal, other psychiatric disorders, or medical illness. Intrusive trauma memories, avoidance of trauma-linked reminders, sustained changes in cognition and mood, and heightened reactivity make PTSD more likely when they follow a qualifying trauma and meet diagnostic criteria. Substance-specific impairment, loss of control, craving, and continued use despite adverse consequences support evaluation for SUD.

When symptoms fluctuate rapidly around substance exposure, timing is critical. Alcohol or sedative withdrawal can cause tremor, agitation, autonomic activation, and perceptual disturbances; stimulant intoxication can involve severe anxiety, paranoia, chest pain, or psychosis; cannabis or stimulant use can complicate sleep and mood assessment. PTSD assessment should consider recent exposure, medical findings, medication effects, the withdrawal window, and whether a history of symptoms predates substance use. Co-occurring psychosis, bipolar disorder, depression, obsessive-compulsive symptoms, pain, and head injury warrant their own assessments where indicated.

A complete trauma and substance-use history

A high-quality assessment builds a timeline: traumatic events; first onset of symptoms; pattern and quantity of each substance; episodes of intoxication, overdose, withdrawal, and treatment; changes in use around reminders; psychiatric symptoms during sustained periods of less use; prescribed medications; medical illness; and previous responses to interventions. Clinicians also ask about present safety, housing, relationships, violence, pregnancy when relevant, and whether the person can attend and engage in care. This helps distinguish independent disorders, substance-induced syndromes, and disorders that genuinely co-occur.

History-taking should be paced and consensual. A patient can disclose enough to assess eligibility and safety without providing a detailed trauma narrative at the first appointment. Repeated insistence on graphic details can impair trust and is rarely necessary for initial triage. Private interviewing, transparent confidentiality practices, trained interpretation, and language that describes behavior without blame make accurate disclosure more likely. SAMHSA TIP 57 places these principles within trauma-informed behavioral health services.

Screening, diagnostic interviews, and repeated measurement

Screening identifies who may need further evaluation; assessment integrates clinical information; diagnosis applies formal criteria. For PTSD, the PC-PTSD-5 is a short primary-care screen, and the PCL-5 measures symptom severity and can support provisional assessment and monitoring. The CAPS-5 is a structured interview used for diagnostic assessment. Scores should be interpreted in the context of clinical presentation, population, and timing rather than as self-sufficient diagnoses.

Substance screening may use validated tools suited to the substance and healthcare setting, followed by an interview covering DSM-5-TR criteria, impairment, safety and readiness for care. Clinicians record outcomes separately for PTSD symptom severity, substance use or abstinence goals, overdose risk, cravings, medical status, functioning, and treatment engagement. Improvement in one dimension should not conceal deterioration in another. Repeating measurement after stabilization and over the course of therapy can clarify whether overlapping symptoms persist independently.

Medical and Psychiatric Safety Comes First

Acute emergencies require medical attention before elective psychotherapy sessions. A person who is unresponsive, breathing slowly or irregularly after possible opioid exposure, or showing signs of overdose needs emergency services immediately. Naloxone or another appropriate opioid overdose reversal medication should be administered when available while emergency help is obtained; responders should remain with the person and support breathing according to emergency instructions. The CDC overdose guidance describes these danger signs and actions.

Alcohol withdrawal and withdrawal from benzodiazepines or related sedatives can cause seizures, delirium, and other life-threatening complications, especially with physiological dependence or a history of severe withdrawal. Individuals at risk need professional assessment and a medically managed plan rather than abrupt self-directed cessation. Severe confusion, seizures, hallucinations with instability, or profound autonomic symptoms warrant urgent emergency evaluation. Detoxification and stabilization manage an acute physiological state; continuing evidence-based addiction treatment remains necessary to address the longer-term disorder. ASAM's alcohol withdrawal guideline and its benzodiazepine tapering guideline provide clinical frameworks.

Suicidal thoughts, recent attempts, immediate threats of violence, inability to remain safe, severe psychosis, stimulant-related chest pain, and significant medical complications require prompt risk assessment and, when imminent, emergency intervention. A trauma-SUD plan includes explicit coordination between crisis services and continuing treatment. Stabilization is a clinical task, not a requirement to achieve an arbitrary period of abstinence before all PTSD care can begin. Clinical decisions depend on alertness, capacity to consent, current intoxication and withdrawal, immediate danger, and whether a person can participate safely.

What Integrated Treatment Actually Means

Concurrent, coordinated, and fully integrated care

Concurrent treatment means that care for PTSD and SUD occurs during the same period rather than waiting for one disorder to disappear. Coordinated care links different professionals through a shared plan; co-located care offers services in the same setting; fully integrated care combines expertise and interventions in one team or protocol. These are practical delivery arrangements, not interchangeable guarantees of treatment quality. SAMHSA's integrated-care guidance describes coordinated, co-located, and fully integrated models.

A comprehensive plan can include trauma-focused PTSD psychotherapy, evidence-based SUD medications when indicated, behavioral addiction treatment, withdrawal management when needed, overdose prevention, sleep and depression care, case management, and support for housing or relationships. The order and pace of individual components respond to medical acuity, patient choice, substance class, cognitive state, and social conditions. For many patients these components overlap; for some, a brief phase of acute medical stabilization precedes trauma processing. The presence of SUD alone does not justify indefinite deferral of PTSD treatment.

Trauma-informed care and trauma-focused therapy serve different functions

Trauma-informed care is an organizational and clinical approach that aims to make services safer, more predictable, respectful, and collaborative for people who may have experienced trauma. It can be practiced in emergency departments, detoxification units, primary care, SUD programs, and psychotherapy settings whether or not PTSD has been diagnosed. Its goals include reducing retraumatization and improving engagement. Trauma-informed care principles are strongly supported as service standards, while estimates of their independent causal effects on PTSD or substance-use outcomes remain harder to establish because programs combine many components.

Trauma-focused psychotherapy directly works with trauma-related memories, meanings, avoidance, and conditioned responses using a structured evidence-based protocol. Prolonged exposure (PE), cognitive processing therapy (CPT), and eye movement desensitization and reprocessing (EMDR) are PTSD-focused interventions with established efficacy in appropriate populations. Providing a welcoming, trauma-informed environment is valuable but does not itself deliver the active components of a trauma-focused treatment. The VA/DoD PTSD guideline recommends that co-occurring SUD not prevent access to guideline-supported PTSD therapies.

Psychotherapy: What the Comparative Evidence Shows

Trauma-focused therapy alongside SUD treatment

An important Cochrane review of randomized studies found that individual trauma-focused psychological therapy delivered alongside substance-use treatment reduced PTSD symptoms more than usual or minimal care immediately after treatment and at later follow-up. Improvements in substance use were less consistent at treatment end, with small benefits at some later time points; treatment completion was also lower in some trauma-focused groups. The authors rated much of the evidence low or very low quality, pointing to small studies, methodological limitations, short follow-up, and the exclusion of some highly complex patients. These qualifications matter when interpreting efficacy for an individual with severe instability. See the Cochrane systematic review by Roberts and colleagues.

Later syntheses reinforce the relative advantage of trauma-focused interventions for PTSD symptom outcomes while clarifying that no single protocol is best for every individual. In a systematic review and network meta-analysis, Project Harmony examined 39 studies, including 24 randomized trials in the network analysis. Integrated trauma-focused treatment produced greater end-of-treatment PTSD symptom reductions than integrated non-trauma-focused psychotherapy, alcohol-or-drug-focused psychotherapy, and control psychotherapies; reported standardized mean differences for those contrasts were approximately -0.30, -0.29, and -0.43, respectively. Substance-use outcomes were influenced substantially by therapies and medications directed at the substance disorder. The comparison must be interpreted with heterogeneity in trials and imperfect reporting of adverse events. See Project Harmony, Psychological Bulletin.

COPE: exposure therapy integrated with relapse prevention

Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure (COPE) combines core prolonged-exposure procedures for PTSD with relapse prevention and skills targeting substance use. It addresses trauma memories, avoidance, cravings, high-risk situations, and ongoing patterns of consumption within one structured clinical approach. COPE has been tested in veteran and non-veteran samples, including people with substantial clinical complexity. A trained therapist evaluates current safety and suitability, explains the rationale, collaborates on goals, and measures symptoms and substance-use outcomes across care.

The VA National Center for PTSD identifies COPE as a particularly studied integrated trauma-focused protocol and reports trials with better PTSD outcomes than several comparison conditions. Evidence for reduced substance use is more variable than evidence for PTSD improvement, and available findings do not justify promising remission from both conditions after a fixed number of sessions. Clinical safety plans, patient preferences, access to trained practitioners, and ongoing substance-specific care remain essential.

PE, CPT, and EMDR in patients who also have an SUD

A patient may receive PE, CPT, or EMDR from a PTSD clinician while another clinician provides effective SUD treatment. Therapy can be coordinated even when it is not packaged as one integrated protocol. Exposure-based interventions target avoidance and learned fear; CPT focuses on maladaptive trauma-related interpretations; EMDR uses a structured trauma-memory processing protocol. The precise fit depends on clinical presentation, training, treatment availability, informed choice, and evidence for the particular population. Trauma-focused work can evoke temporary distress, which makes collaborative monitoring important, but randomized evidence does not establish that SUD automatically makes it unsafe or ineffective.

The VA/DoD guideline's recommendation for co-occurring conditions and the VA practice synthesis explicitly support access to appropriate trauma-focused therapies alongside SUD treatment. Readiness is a clinical judgment concerning current medical stability, cognitive participation, and consent, rather than a blanket rule requiring a prolonged substance-free interval.

Seeking Safety and other non-trauma-focused approaches

Seeking Safety teaches coping and safety skills without direct trauma-memory processing. It can be acceptable to patients and services, and its practical modules may be useful for stabilization and engagement. However, comparative trials and systematic reviews generally have not demonstrated superior reductions in core PTSD symptoms over SUD treatment alone or usual care. In a randomized comparison summarized by the VA, COPE produced greater PTSD symptom improvement and greater likelihood of PTSD remission than Seeking Safety, while substance-use outcomes showed a different pattern. This is a finding about efficacy for PTSD symptoms, not a judgment about the value of supportive skills or a patient's preference for them.

Programs should therefore distinguish supportive stabilization, evidence-based addiction interventions, and therapies designed to treat PTSD itself. Presenting every coping-skills group as equivalent to trauma-focused treatment would misrepresent the literature. The Cochrane review, Project Harmony, and VA comparative review support that distinction.

Dropout, adverse events, and generalizability

Higher symptom improvement among treatment completers cannot substitute for analysis of retention and missing outcomes. PTSD-SUD trials often struggle with dropout, differences in comparator care, self-reported use measures, small samples, and restricted inclusion criteria. Some studies exclude patients with immediate suicidality, severe cognitive impairment, uncontrolled psychosis, or unstable medical conditions. Research populations may overrepresent particular substances, age groups, healthcare systems, or veteran populations. Reported adverse events are not uniform across trials, and the absence of a detected difference does not prove that risk is zero.

In practice, treatments are evaluated on a broader set of outcomes: clinically meaningful PTSD improvement, substance-use trajectories, overdose prevention, adverse effects, retention, housing, functioning, patient-defined recovery goals, and satisfaction with care. Individual needs can justify adapting the setting or pace while maintaining access to interventions with the best available evidence. Project Harmony's individual-patient analysis helps compare modalities but cannot eliminate all differences in clinical context.

Medication Treatment and Drug-Specific Considerations

Treat the substance use disorder with evidence-based medicine

When opioid use disorder is present, buprenorphine or methadone treatment can reduce mortality risk and support sustained care; extended-release naltrexone is another option for selected individuals with appropriate opioid-free status and clinical evaluation. For alcohol use disorder, medications such as naltrexone and acamprosate may be appropriate depending on goals, medical conditions, and contraindications. Medications for nicotine dependence support cessation. Contingency management is a leading evidence-based behavioral intervention for stimulant use disorder, while no medication has the same broadly established regulatory status for stimulant use disorder as methadone or buprenorphine has for opioid use disorder. Substance-specific treatment selection belongs in a coordinated medical assessment.

PTSD comorbidity does not make effective addiction medication dispensable. SUD pharmacotherapy can continue while evidence-based PTSD psychotherapy is offered. The VA PTSD-SUD treatment review identifies improvement in alcohol outcomes associated with substance-directed pharmacotherapies in comparative research. The CDC guidance on opioid use disorder treatment emphasizes effective ongoing treatment rather than withdrawal management alone.

Medications for PTSD require their own indication

Medication decisions for PTSD address its symptoms and the person's psychiatric and medical profile. Selected antidepressants have guideline support for PTSD in adults when appropriate, but PTSD medication evidence should not be confused with evidence for treating the substance-use disorder. A medication may improve one condition while leaving the other substantially unchanged. Research on adding PTSD-targeted pharmacotherapy to SUD treatment is heterogeneous; no single combined medication regimen is established for all PTSD-SUD presentations.

Benzodiazepines warrant special attention. Although they have defined roles in professionally managed alcohol withdrawal and other conditions, they are not supported as ongoing treatment for core PTSD symptoms, and co-exposure with opioids or alcohol can increase sedation and respiratory risk. People already physically dependent on prescribed sedatives need individualized medical plans; abrupt cessation can be dangerous. The VA/DoD PTSD guideline and ASAM benzodiazepine guidance support careful indication review and supervised management.

Cannabis, alcohol, opioids, stimulants, and polysubstance exposure

Different substances create different clinical priorities. Alcohol may be used for sleep or emotional numbing but can worsen sleep architecture and introduce dangerous withdrawal. Opioids involve overdose and respiratory suppression, often heightened by sedative co-use. Stimulants can intensify arousal, insomnia, cardiovascular symptoms, or psychosis. Cannabis use may co-occur with PTSD symptoms, but cannabis products are not established treatments for PTSD; the VA review of cannabis and PTSD advises evidence-based treatment for both disorders instead.

Polysubstance patterns complicate attribution: sedation, agitation, sleep disturbance, dissociation, and craving may reflect interacting substances or changing withdrawal states. Clinical assessment accounts for the actual mixture of drugs and prescribed medicines, rather than relying on a single drug label. Harm-reduction measures, overdose education, naloxone access for opioid exposure, and infection prevention can accompany treatment regardless of whether immediate abstinence is the patient's selected goal.

Trauma-Informed Recovery Beyond the Therapy Room

Safety, agency, trust, and access

Services can unintentionally reproduce feelings of vulnerability through coercive practices, abrupt changes, public disclosure of confidential information, or inconsistent explanations. Trauma-informed practice builds transparent choices, predictable appointments, confidential conversations, attention to cultural and linguistic context, and respectful responses to missed visits. These features can support engagement in SUD treatment and make trauma-focused referrals feasible. They also serve patients without formal PTSD diagnoses. SAMHSA's current trauma-informed framework defines organizational principles rather than a single manualized psychotherapy.

People may need practical support before they can participate consistently: reliable transportation, safe housing, medication access, protection from ongoing violence, childcare, and care that does not require retelling traumatic events to multiple disconnected providers. Integrating these supports with clinical treatment expands opportunity for recovery but should not be described as a substitute for treating severe PTSD or SUD. Case management and peer recovery support can have meaningful roles alongside evidence-based interventions.

Recurrence, remission, and functioning

A return to substance use after improvement can be a clinical signal to reassess triggers, medication access, traumatic stress, withdrawal, social instability, and treatment fit. It is not a moral verdict or proof that previous gains disappeared. PTSD symptoms can also recur after new threats or reminders. Diagnostic remission, reduced frequency or consequences of use, PTSD symptom improvement, and the reconstruction of functioning are distinct outcomes. Recovery plans should state what is being measured and why it matters to the individual.

Maintenance can include continuing medication for SUD, booster psychotherapy sessions when indicated, trauma-related coping work, safer social environments, overdose prevention, and community support. Some individuals prioritize abstinence; others initially prioritize reduced harm, safety, and function. The clinical task is to match goals with risks and available evidence, to revisit them collaboratively, and to monitor both disorders over time. SAMHSA's co-occurring disorders framework emphasizes continuity and whole-person care.

Special Populations and Contexts

Adolescents and young adults

Trauma exposure and substance experimentation can overlap during periods when emotion regulation, relationships, and risk perception are still developing. Assessment should consider age-specific diagnostic tools, family safety, school context, confidentiality, exploitation, developmental functioning, and the possibility of ongoing abuse. Evidence from adult PTSD-SUD psychotherapy trials cannot be transferred unchanged to adolescents. Developmentally appropriate trauma treatment and evidence-based youth substance care require clinicians trained for the age group; safeguarding obligations and privacy rules vary by jurisdiction.

Pregnancy and postpartum care

Pregnancy raises medical questions involving fetal exposure, withdrawal, medication continuity, obstetric complications, intimate partner violence, and postpartum mood and trauma symptoms. Sudden unsupervised cessation of substances or prescribed medications can create risk. Care teams should coordinate obstetric, psychiatric, and addiction services using nonpunitive communication. Pregnant patients with opioid use disorder generally benefit from evidence-based medication treatment under obstetric and addiction supervision; a purely punitive or withdrawal-only response undermines continuity. Decisions are individualized, with the pregnant patient's consent and safety central.

Veterans, refugees, and people exposed to repeated violence

Some patients have experienced military combat, displacement, sexual violence, torture, community violence, occupational trauma, or multiple interlocking stressors. Many studies of combined PTSD-SUD treatment involve veterans, providing valuable evidence but imperfect generalizability to displaced civilians or settings with fewer healthcare resources. Cultural interpretations of distress, language, legal vulnerability, discrimination, and access to confidential services shape engagement. Clinicians should evaluate ongoing threats instead of treating every trauma response as a memory of an exclusively past event.

Chronic pain, sleep disturbance, and complex comorbidity

Chronic pain can sustain both trauma-related distress and substance-related harms, especially when opioids, alcohol, sedatives, or other drugs are used for symptom control. Sleep symptoms may persist after improvement in PTSD or substance use and deserve assessment of medical, behavioral, and medication-related causes. Severe depression, self-harm risk, psychosis, and bipolar symptoms require integrated assessment and appropriate specialty care. A broad integrated plan sets priorities without assuming that all symptoms share one mechanism or will respond to a single therapy.

Strength of Evidence and Remaining Scientific Questions

The strongest clinical conclusion is that co-occurring SUD should not automatically block trauma-focused PTSD therapy, and that both disorders warrant evidence-based assessment and care. Comparative meta-analyses favor trauma-focused interventions for PTSD symptom reduction, particularly when accompanied by SUD treatment. The evidence for which integrated protocol optimizes substance-use outcomes, long-term functional recovery, or retention across every substance class is more variable. Project Harmony and the VA guideline support these graded conclusions.

Established clinical principles include professional assessment of dangerous intoxication and withdrawal; overdose reversal with naloxone when opioids are involved; pharmacotherapies for specific SUDs; structured trauma-focused psychotherapy for PTSD; and coordinated clinical decisions. Evidence remains context-dependent for the best sequencing in unstable cases, comparative effectiveness of integrated versus coordinated separate services, long-term maintenance after combined therapy, and interventions tailored to highly excluded research groups. Trauma-informed service principles have substantial professional consensus but variable direct outcome-evaluation designs. Claims about universal biological pathways, guaranteed cure, or one obligatory model of recovery exceed the evidence.

Future empirical work needs adequately powered trials that specify substance classes, trauma exposure and PTSD criteria, baseline risk, adverse events, retention, patient preferences, and outcomes after treatment ends. Pragmatic studies of non-veteran settings, adolescent and perinatal populations, diverse cultural groups, homelessness, and concurrent severe psychiatric illness may improve generalizability. Observational research should distinguish association from causation and examine how housing, violence exposure, treatment access, and policy shape real-world outcomes.

Frequently Asked Questions

Can trauma cause a substance use disorder?

Trauma exposure is an established risk correlate and can contribute through distress, avoidance, learning, and adverse social environments. It is not a sufficient explanation for every SUD, and the association does not establish a simple one-way causal law. Genetic, developmental, substance-specific, and environmental pathways also matter. Clinical assessment identifies the person's actual pattern rather than inferring etiology from a trauma history.

Does every person with trauma and addiction have PTSD?

No. Trauma exposure and distress can occur without the symptom combination, duration, exposure criteria, and impairment required for PTSD. A person may instead have depression, anxiety, sleep disturbance, another trauma-related presentation, or no diagnosable mental disorder. PTSD screening leads to further assessment and, where indicated, structured diagnostic interviewing.

Must a person stop using substances completely before PTSD therapy begins?

A mandatory prolonged abstinence interval is not supported as a universal prerequisite. Concurrent treatment can be beneficial. Immediate intoxication, medically risky withdrawal, emergency safety concerns, or inability to participate may require stabilization before an individual trauma-processing session, while addiction care and engagement continue. The VA guidance supports access to evidence-based treatment for both conditions.

Can PTSD therapy make substance use worse?

Distressing memories may temporarily increase arousal, so safety planning and monitoring are clinically important. Available randomized research does not show that trauma-focused treatment automatically worsens substance use when appropriately provided alongside SUD treatment. Retention and substance-related outcomes differ across trials, and clinicians adjust the plan when a patient's risks or symptoms change. The Cochrane review details benefits and limitations.

Is trauma-informed care the same as treating PTSD?

Trauma-informed care organizes services around safety, transparency, collaboration, and choice. PTSD treatment involves a clinical intervention shown to reduce core PTSD symptoms, typically using a structured trauma-focused method. A good care pathway can provide both. Staff awareness of trauma does not replace evidence-based SUD medication or PTSD psychotherapy when indicated.

Is EMDR or prolonged exposure safe with addiction?

Co-occurring SUD alone does not rule out trauma-focused treatment. Suitability depends on current medical stability, ability to participate, consent, substance-specific risks, concurrent care, and therapist competence. Evidence supports access to guideline-recommended trauma-focused approaches, with individualized monitoring rather than automatic exclusion. The VA clinical synthesis provides a practitioner-oriented evidence review.

What matters most in long-term recovery from trauma and substance use disorders?

Meaningful recovery follows improvement in both conditions and in everyday functioning. Sustained access to evidence-based SUD treatment, effective PTSD care, supportive relationships, safer environments, housing, patient-defined goals, and continuing assessment all matter. Different individuals have different sequences and outcomes; clear measurement and flexible, coordinated care make the plan responsive to changing needs.

Related Articles

Cluster Substance Use Disorders and Addiction Recovery — the central scientific chapter connecting diagnostic concepts, substance-specific disorders, treatment, and recovery.

What Is a Dual Diagnosis? Substance Use and Co-Occurring Mental Disorders — the general clinical framework for co-occurring mental and substance use disorders.

Anxiety and Substance Use: Self-Medication, Withdrawal, and Comorbidity — the separately owned anxiety and substance-use overlap.

Stress and Addiction: Coping, Negative Reinforcement, and Relapse — negative reinforcement, stress responses, and recurrence risk.

Substance Use Disorders and Suicide Risk: Evidence, Assessment, and Safety — substance-specific suicide-risk assessment and safety.

Growing Up With Parental Substance Use: Childhood Adversity and Adult Outcomes — a distinct developmental perspective on parental substance use and childhood adversity.

References

American Society of Addiction Medicine. (2020). The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management. Official guideline.

American Society of Addiction Medicine. (2025). Joint Clinical Practice Guideline on Benzodiazepine Tapering. Official guideline.

Centers for Disease Control and Prevention. (2024). Five Things to Know About Naloxone. CDC.

Centers for Disease Control and Prevention. (2024). Opioid Use Disorder: Treating. CDC.

Hien, D. A., et al. (2023). Project Harmony: A meta-analysis with individual patient data on behavioral and pharmacologic trials for comorbid posttraumatic stress and alcohol or other drug use disorders. American Journal of Psychiatry, 180, 155–166. https://doi.org/10.1176/appi.ajp.22010071.

Hien, D. A., Papini, S., Saavedra, L. M., Bauer, A. G., Ruglass, L. M., et al. (2024). Project Harmony: A systematic review and network meta-analysis of psychotherapy and pharmacologic trials for comorbid posttraumatic stress, alcohol and other drug use disorders. Psychological Bulletin, 150(3), 319–353. https://doi.org/10.1037/bul0000409.

Norman, S. B., Hicks, T., Klein, A., and Hamblen, J. (2025). Treatment of Co-Occurring PTSD and Substance Use Disorder in VA. National Center for PTSD. VA clinical evidence synthesis.

Prins, A., et al. (2016). The Primary Care PTSD Screen for DSM-5: Development and evaluation within a veteran primary care sample. Journal of General Internal Medicine, 31, 1206–1211. https://doi.org/10.1007/s11606-016-3703-5.

Roberts, N. P., Roberts, P. A., Jones, N., and Bisson, J. I. (2016). Psychological therapies for post-traumatic stress disorder and comorbid substance use disorder. Cochrane Database of Systematic Reviews, CD010204. https://doi.org/10.1002/14651858.CD010204.pub2.

Simpson, T. L., Rise, P., Browne, K. C., Lehavot, K., and Kaysen, D. (2019). Clinical presentations, social functioning, and treatment receipt among individuals with comorbid lifetime PTSD and alcohol use disorders versus drug use disorders: Findings from NESARC-III. Addiction, 114, 983–993. https://doi.org/10.1111/add.14565.

Substance Abuse and Mental Health Services Administration. (2014). Trauma-Informed Care in Behavioral Health Services (TIP 57). NCBI Bookshelf.

Substance Abuse and Mental Health Services Administration. (2020). Substance Use Disorder Treatment for People With Co-Occurring Disorders (TIP 42). Official clinical guidance.

Substance Abuse and Mental Health Services Administration. (2025). Screening and Treatment of Co-Occurring Disorders. SAMHSA.

Substance Abuse and Mental Health Services Administration. (2026). Trauma-Informed Approaches and Programs. SAMHSA.

U.S. Department of Veterans Affairs and Department of Defense. (2023). VA/DoD Clinical Practice Guideline for Management of Posttraumatic Stress Disorder and Acute Stress Disorder. Clinical guideline.

U.S. Department of Veterans Affairs, National Center for PTSD. (2024). Cannabis Use and PTSD Among Veterans. VA.

U.S. Department of Veterans Affairs, National Center for PTSD. (n.d.). Clinician-Administered PTSD Scale for DSM-5 (CAPS-5). VA.

U.S. Department of Veterans Affairs, National Center for PTSD. (n.d.). PTSD Checklist for DSM-5 (PCL-5). VA.

U.S. Department of Veterans Affairs, National Center for PTSD. (n.d.). Primary Care PTSD Screen for DSM-5 (PC-PTSD-5). VA.